Beta-secretase 1

Overview

Beta-secretase 1 (BACE1), also known as β-site amyloid precursor protein-cleaving enzyme 1, is a transmembrane aspartyl protease encoded by the BACE1 gene in humans. It is the rate-limiting enzyme responsible for the first proteolytic cleavage of amyloid precursor protein (APP), generating the soluble APP-beta fragment and the membrane-bound C99 stub that is subsequently cleaved by gamma-secretase to produce amyloid-beta (Aβ) Peptides. The accumulation and aggregation of these Aβ Peptides into plaques in the brain is a hallmark of Alzheimer's disease (AD) and forms the basis of the amyloid cascade hypothesis — currently the most widely accepted theoretical framework for understanding AD pathogenesis. Because BACE1 sits at a critical upstream node in this cascade, it has been intensively pursued as a therapeutic target for disease-modifying therapies in AD.

Beyond its role in amyloid processing, BACE1 is expressed broadly in the central nervous system and participates in the regulation of synaptic plasticity, myelination, and neuregulin signaling. Its inhibition, while therapeutically attractive, must therefore be carefully calibrated to avoid disrupting these physiological functions. This dual nature — as both a pathological driver and a functionally important enzyme — has made BACE1 one of the most challenging yet compelling targets in neuropharmacology, driving decades of medicinal chemistry, structural biology, and clinical investigation.

Focus of Latest Publications

Recent publications on Beta-secretase 1 (BACE1) continue to center on its role as a therapeutic target in Alzheimer’s disease and, more broadly, on strategies to modulate its activity in disease-relevant settings. Several studies focused on identifying or prioritizing small-molecule BACE1 inhibitors. One report described natural compounds isolated from Fernandoa adenophylla, combining in vitro enzyme assays with computational tools and kinetic analyses; among the tested compounds, lapachol was identified as the most effective BACE1 inhibitor in that series. Another study introduced NeuroBACE-ML, a reliability-aware machine-learning framework built from curated human BACE1 bioactivity data to screen small-molecule libraries, reporting strong performance on held-out and external validation datasets and positioning the tool for early-stage inhibitor prioritization.

Other recent work examined BACE1 within multi-target therapeutic strategies for Alzheimer’s disease. Hydrazide-hydrazone indole congeners were evaluated as multi-faceted inhibitors of acetylcholinesterase, BACE1, and monoamine oxidase-B, with in vitro, in vivo, and in silico profiling showing that selected compounds inhibited multiple AD-relevant enzymes and improved spatial memory in diseased mice; compound 3f showed the most consistent overall performance. A review article also summarized medicinal chemistry advances in BACE1 inhibitor development, emphasizing the enzyme’s central role in Beta amyloid generation and discussing the progression of inhibitor generations, including issues of brain penetration, potency, safety, and clinical trial setbacks.

BACE1 has also been investigated through nucleic acid-based and translational approaches. In one study, small interfering RNA targeting BACE1 was co-loaded with rutin into a multifunctional nanoparticle system designed to reduce Beta amyloid production and aggregation while also mitigating neuroinflammation. This construct silenced BACE1 expression, reduced amyloid-related pathology, and improved memory and cognition in Alzheimer’s disease mice. In another publication, the BACE1 inhibitor lanabecestat was revisited in a re-analysis of a clinical trial using artificial intelligence-based patient clustering; while the overall trial remained negative, subgroup analysis suggested slower disease worsening in one semantically defined patient cluster.

Beyond neurodegeneration, BACE1 was also explored in cancer biology. A rectal cancer study investigated whether BACE1 overexpression could affect ST6GAL1-mediated chemoradiation resistance, based on the premise that BACE1 cleaves ST6GAL1 and might influence treatment response. Collectively, these publications reflect ongoing interest in BACE1 as both a direct enzymatic target and a mechanistic node in therapeutic development, especially for Alzheimer’s disease, while also extending to other disease contexts.

Key Publications

• NEWJul Beta-site Amyloid Precursor Protein Cleaving Enzyme 1 Overexpression Abrogates ST6GAL1 Mediated Rectal Cancer Chemoradiation Resistance. (Cancer genomics & proteomics, 2026, PMID 42373231): "We aimed to elucidate whether beta-site amyloid precursor protein cleaving enzyme 1 (BACE1), which cleaves ST6GAL1, has a role in treatment response to CRT and whether its overexpression (OE) could improve response to CRT."
• May Turning failure into success: how artificial intelligence can help personalize therapies and re-use patient data. (Purinergic signalling, 2026, PMID 42213219): "testing Lanabecestat, a BACE1 inhibitor decreasing β-amyloid production in Alzheimer's disease, for which traditional analysis reported no efficacy."
• Apr Natural compounds from Fernandoa adenophylla (Wall. ex G.Don) Steenis as beta-secretase 1 and monoamine oxidase-b inhibitors: in vitro and computational evidence. (Journal of computer-aided molecular design, 2026, PMID 42032388): "Lapachol (1) resulted to be the most effective BACE-1 inhibitor of the set, while peshawaraquinone (3) strongly inhibited MAO-B."
• Jul NeuroBACE-ML: A reliability-aware screening framework for high-throughput prioritization of potent BACE1 inhibitors. (Journal of molecular graphics & modelling, 2026, PMID 42008960): "Beta-site amyloid precursor protein cleaving enzyme 1 (BACE1) is a key enzyme in amyloid-β generation and remains an important target in Alzheimer's disease (AD) drug discovery."
• Mar In vitro, in vivo, and in silico profiling of optimized hydrazide-hydrazone indole congeners as multi-faceted AChE, BACE1, and MAO-B inhibitors for Alzheimer's disease therapy. (Bioorganic chemistry, 2026, PMID 41865568): "Further in vitro profiling demonstrated their inhibitory potencies across additional AD-relevant enzymes, including AChE, BChE, BACE-1, MAO-A, MAO-B, and COX-2."
• Apr Developments on BACE 1 Inhibitors as Anti-Alzheimer Agents: A Perspective on Medicinal Chemistry-Based Advances. (Archiv der Pharmazie, 2026, PMID 41838033): "...the amyloid cascade hypothesis remains the most widely accepted theory, as it suggests that β-site amyloid precursor protein-cleaving enzyme 1 (BACE1) plays a critical role in the generation of Aβ peptides."
• Apr An anti-inflammatory neuroenhancer mitigates amyloid-β pathology to improve Alzheimer's disease therapy. (Materials today. Bio, 2026, PMID 41696149): "RB@LCP-AR not only releases siBACE1 to silence BACE1 expression and block Aβ production from the cleavage of amyloid precursor protein, but also releases Rutin to suppress the Aβ aggregation."